Clinical efficacy of decitabine combined with half dose CAG regimen in treatment of patients with relapsed/refractory acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2018.07.005
- VernacularTitle:地西他滨联合半量CAG方案治疗复发难治急性髓系白血病效果观察
- Author:
Hongtao ZHANG
1
;
Yaqing FENG
;
Fang ZHAO
;
Jianhua MA
;
Yanfang ZHANG
;
Xi LIU
Author Information
1. 037008,山西省大同市第三人民医院血液内科
- Keywords:
Leukemia,myeloid,acute;
Drug therapy,combination;
Decitabine;
Refractory;
Recurrence
- From:
Journal of Leukemia & Lymphoma
2018;27(7):404-406,409
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of decitabine combined with half dose CAG regimen in patients with relapsed/refractory acute myeloid leukemia (AML).Methods Clinical data of 8 patients with relapsed/refractory AML who took the therapeutic regimen with decitabine combined with half dose CAG regimen in the Third People's Hospital of Datong from January 2015 to January 2017 were collected.The clinical efficacy and adverse effects were observed.Results After one course treatment by decitabine combined with half dose CAG regimen,3 patients achieved complete remission,and 2 patients achieved partial remission.The major adverse reactions were myelosuppression and infection,8 patients appeared grade Ⅲ-Ⅳ myelosuppression,5 patients appeared infection,2 patients appeared grade Ⅰ abnormality of liver and no treatment-related death occurred.Conclusion Decitabine combined with half dose CAG regimen is effective for relapsed/refractory AML,and this regimen is worthy of further study.
